CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103399
035-os BibID:(Scopus)85149171419 (WoS)000952863200010
Első szerző:Béldi Tibor (orvos)
Cím:The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients : a single centre experience / Béldi Tibor, Vincze Anett, Miltényi-Szabó Balázs, Varga Zsófia, Szabó Katalin, Griger Zoltán, Nagy-Vincze Melinda
Dátum:2023
ISSN:0392-856X 1593-098X
Megjegyzések:Objectives: Pandemic caused by coronavirus disease (COVID-19) determines the life of clinicians and patients since 2 years. We have a lot of information about disease course, treatment and protection against virus, but less on the prognosis of infection in patients with idiopathic inflammatory myopathies (IIM). Also few data are available on triggered humoral response and side effects after vaccination. Methods: Our goal was to assess by a retrospective cross-sectional study the above data in our cohort (176 IIM patients) by identifying COVID-19 positive patients and follow disease course. Incidence and complications of vaccination were determined by questionnaires. 101 patients volunteered for complex blood test. Results: By June 1st, 2021 significantly higher incidence of COVID 19 infections (34.7%) were identified comparing to the national prevalence (8.2%). A third of these infections occurred asymptomatically or mild. Patients requiring hospitalisation had a significantly longer disease duration and a higher incidence of anti-Jo-1 antibody. All patients infected by COVID-19 became seropositive regardless the immunosuppressive therapy or symptoms severity. 54.3% of the patients received anti-COVID-19 vaccine. 72.3% of patients became seropositive after vaccination. Higher antibody titer against spike protein was detected after Pfizer-BioNTech vaccination compared to others. Patients receiving steroid therapy had decreased post-vaccination antibody response compared to those without steroid treatment. No major post-vaccination infection was observed. Conclusions: Based on our results, myositis may be associated with an increased risk of COVID-19 infection. Independent risk factor for hospitalisation are longer disease duration and anti-Jo1 positivity. Anti-SARS-CoV2 vaccines seem safe and tolerable and strongly recommended for that population.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
myositis
interstitial lung disease
COVID infection
vaccination
Megjelenés:Clinical And Experimental Rheumatology. - 41 : 2 (2023), p. 254-260. -
További szerzők:Vincze Anett (1993-) Miltényi-Szabó Balázs (1996-) (orvostanhallgató) Varga Zsófia (1992-) (molekuláris biológus) Szabó Katalin (1991-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM109477
035-os BibID:(Scopus)85150818434 (WoS)000949012200001
Első szerző:Nagy-Vincze Melinda (orvos)
Cím:Incidence, features and outcome of disease relapse after Covid-19 vaccination in patients with idiopathic inflammatory myopathies / Nagy-Vincze Melinda, Béldi Tibor, Szabó Katalin, Vincze Anett, Miltényi-Szabó Balázs, Varga Zsófia, Varga József, Griger Zoltán
Dátum:2023
ISSN:0148-639X
Megjegyzések:Introduction/Aims Vaccination against coronavirus disease (COVID-19) is relatively safe in patients with idiopathic inflammatory myopathies (IIM), however, myositis flares following vaccination have been poorly studied. We aimed to evaluate the frequency, features and outcomes of disease relapses in patients with IIM following COVID-19 vaccination. Methods A cohort of 176 IIM patients were interviewed after the 3rd wave of the COVID-19 pandemic and followed prospectively. Relapses were determined using the disease state criteria and the outcome of the flares with myositis response criteria, calculating the total improvement score (TIS). Results A total of 146 (82.9%) patients received a vaccination, 17/146 (11.6%) patients had a relapse within 3 months, and 13/146 (8.9%) patients within one month. The relapse rate of unvaccinated patients was 3.3%. Three months after the post-vaccination relapses, 70.6% of the patients (12/17) achieved an improvement of disease activity (average TIS score: 30?15.81; 7 minor, 5 moderate and 0 major improvements). Six months after flares improvement was detected in 15/17(88.2%) of relapsed patients (average TIS score: 43.1?19.53; 3 minimal, 8 moderate and 4 major). Forward stepwise logistic regression analysis revealed that the active state of myositis at the time of injection (p<0.0001; OR:33; CI:9?120) was significantly associated with the occurrence of a relapse. Discussion A minority of the vaccinated IIM patients had a confirmed disease flare after COVID-19 vaccination and the majority of the relapses improved after individualized treatment. An active disease state at the time of vaccination probably contributes to the increased risk of a post vaccination myositis flare.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Covid-19 vaccination
idiopathic inflammatory myopathies
myositis
relapse
flare
Megjelenés:Muscle & Nerve. - 67 : 5 (2023) p. 371-377. -
További szerzők:Béldi Tibor (1994-) (orvos) Szabó Katalin (1991-) (orvos) Vincze Anett (1993-) Miltényi-Szabó Balázs (1996-) (orvostanhallgató) Varga Zsófia (1992-) (PhD hallgató) Varga József (1955-) (fizikus) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1